2025 Japan Adenovirus Vaccine Market Revenue Opportunities Report
Description
The 2025 Japan Adenovirus Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adenovirus vaccine market in Japan include GlaxoSmithKline (GSK), Merck & Co., Johnson & Johnson, and Sanofi. GSK has gained approval from Japan’s Ministry of Health for Arexvy, an RSV vaccine targeting older adults, marking a key expansion in Japan’s vaccine portfolio. Merck & Co. is prominent with its GARDASIL®9 vaccine for HPV-related cancers, showing positive Phase 3 trial results in Japanese males. Johnson & Johnson is known for its adenovirus-based Janssen COVID-19 vaccine, widely used globally, including Japan, authorized under emergency use to combat COVID. Sanofi collaborates with Novavax to commercialize COVID-19 and combination flu vaccines in Japan, strengthening respiratory disease protection.
These companies drive innovation and growth in Japan’s vaccine market, which is valued at USD 4.15 billion as of 2024 and growing steadily. Their activities include regulatory approvals, clinical trials, and strategic partnerships to expand vaccine access. Japan’s strong healthcare infrastructure and government initiatives further support these companies’ participation in adenovirus and other vaccine development efforts. Although companies like Teva Pharmaceuticals and Barr Labs dominate global adenovirus vaccine production, the above players stand out in Japan through licensed products and collaborative agreements tailored to the regional market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adenovirus vaccine market in Japan include GlaxoSmithKline (GSK), Merck & Co., Johnson & Johnson, and Sanofi. GSK has gained approval from Japan’s Ministry of Health for Arexvy, an RSV vaccine targeting older adults, marking a key expansion in Japan’s vaccine portfolio. Merck & Co. is prominent with its GARDASIL®9 vaccine for HPV-related cancers, showing positive Phase 3 trial results in Japanese males. Johnson & Johnson is known for its adenovirus-based Janssen COVID-19 vaccine, widely used globally, including Japan, authorized under emergency use to combat COVID. Sanofi collaborates with Novavax to commercialize COVID-19 and combination flu vaccines in Japan, strengthening respiratory disease protection.
These companies drive innovation and growth in Japan’s vaccine market, which is valued at USD 4.15 billion as of 2024 and growing steadily. Their activities include regulatory approvals, clinical trials, and strategic partnerships to expand vaccine access. Japan’s strong healthcare infrastructure and government initiatives further support these companies’ participation in adenovirus and other vaccine development efforts. Although companies like Teva Pharmaceuticals and Barr Labs dominate global adenovirus vaccine production, the above players stand out in Japan through licensed products and collaborative agreements tailored to the regional market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
